Latest News

Nirsevimab Highly Effective in Preventing RSV-Related LRTD in Healthy Term Infants, Real-World Study Finds
Nirsevimab Highly Effective in Preventing RSV-Related LRTD in Healthy Term Infants, Real-World Study Finds

July 25th 2025

Nirsevimab lowered the risk of RSV-related illness by over 87% and hospitalizations by 98% in a new study.

Influenza Vaccination Reduces Disease Burden in Both Vaccinated and Unvaccinated, Modeling Study Finds
Influenza Vaccination Reduces Disease Burden in Both Vaccinated and Unvaccinated, Modeling Study Finds

July 24th 2025

Phase 3 Trials Begin for Once-Monthly Oral HIV Prevention Pill
Phase 3 Trials Begin for Once-Monthly Oral HIV Prevention Pill

July 17th 2025

FDA Grants Full Approval of Moderna’s COVID-19 Vaccine for High-Risk Children Aged 6 Months to 11 Years
FDA Grants Full Approval of Moderna’s COVID-19 Vaccine for High-Risk Children Aged 6 Months to 11 Years

July 10th 2025

New Data at IAS 2025 Underscore Real-World Success of Long-Acting Injectable HIV Therapies / Image credit: ©Ezume Images/AdobeStock
New Data at IAS 2025 Underscore Real-World Success of Long-Acting Injectable HIV Therapies

July 8th 2025

Video Interviews
Podcasts

More News

© 2025 MJH Life Sciences

All rights reserved.